Brief: Unity Biotechnology Announces Restructuring To Advance Corporate Strategy And Focus On Key Ophthalmology Programs

Unity Biotechnology

03/02/2022 21:07

Feb 3 (Reuters) - UNITY Biotechnology Inc  UBX.O :
    * UNITY BIOTECHNOLOGY ANNOUNCES RESTRUCTURING TO ADVANCE
CORPORATE
STRATEGY AND FOCUS ON KEY OPHTHALMOLOGY PROGRAMS
    * UNITY BIOTECHNOLOGY INC - STRATEGIC REALIGNMENT TO FOCUS
CAPITAL
RESOURCES ON CLINICAL PROGRAMS AND EXTEND CASH RUNWAY INTO Q1
2023
    * UNITY BIOTECHNOLOGY INC - 12-WEEK DATA FROM PHASE 2A STUDY
OF
UBX1325 IN DIABETIC MACULAR EDEMA (DME) EXPECTED MID-2022
    * UNITY BIOTECHNOLOGY INC - 16-WEEK DATA FROM PHASE 2 STUDY
IN WET
AGE-RELATED MACULAR DEGENERATION (WET AMD) EXPECTED IN Q4 2022
    * UNITY BIOTECHNOLOGY - ACTIONS TO PRIORITIZE OPHTHALMOLOGY
PROGRAMS AND IMPLEMENT COST SAVING MEASURES ARE EXPECTED TO
EXTEND CASH RUNWAY INTO Q1 2023
    * UNITY BIOTECHNOLOGY INC - ALL OTHER PIPELINE PROGRAMS WILL
BE
PAUSED TO FOCUS RESOURCES ON OPHTHALMOLOGY PROGRAMS
    * UNITY BIOTECHNOLOGY INC - WILL REDUCE ITS WORKFORCE,
PRIMARILY
IN DISCOVERY RESEARCH, BY APPROXIMATELY 50%

Source text for Eikon:  ID:nGNX7CrmM7 
Further company coverage:  UBX.O 

 ((Reuters.Briefs@thomsonreuters.com;))